Boston Scientific Corporation
0HOY.L · London Stock Exchange · USD
45,41USD
+1,21 (+2,73 %)Stand 11. Nov., 19:14
Kennzahlen
- Eröffnung
- 44,50
- Vortag
- 44,21
- Tagesspanne
- 43,84 – 45,78
- 52 Wochen
- 38,50 – 105,83
- Volumen
- 13.147
- Ø Volumen
- 23.126
- Börsenwert
- 65,82 Mrd. $
- KGV
- 19,0
- Gewinn je Aktie (TTM)
- 2,36
- Dividendenrendite
- 0,0 %
- Beta
- 0,7
- Nächste Zahlen
- 3. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 20,07 Mrd. | 16,75 Mrd. | 14,24 Mrd. | 12,68 Mrd. | 11,89 Mrd. |
| Herstellungskosten | 7,02 Mrd. | 6,48 Mrd. | 4,39 Mrd. | 4,97 Mrd. | 4,43 Mrd. |
| Bruttogewinn | 13,06 Mrd. | 10,27 Mrd. | 9,85 Mrd. | 7,71 Mrd. | 7,46 Mrd. |
| Forschung und Entwicklung | 2,05 Mrd. | 1,62 Mrd. | 1,41 Mrd. | 1,32 Mrd. | 1,2 Mrd. |
| Vertrieb und Verwaltung | 6,89 Mrd. | 5,98 Mrd. | 5,19 Mrd. | 4,52 Mrd. | 4,36 Mrd. |
| Operatives Ergebnis | 4,07 Mrd. | 2,64 Mrd. | 2,34 Mrd. | 1,82 Mrd. | 1,92 Mrd. |
| EBITDA | 5,44 Mrd. | 3,94 Mrd. | 3,61 Mrd. | 2,74 Mrd. | 2,92 Mrd. |
| Nettogewinn | 2,89 Mrd. | 1,85 Mrd. | 1,59 Mrd. | 698 Mio. | 1,04 Mrd. |
| Gewinn je Aktie (verwässert) | 1,94 | 1,25 | 1,07 | 0,45 | 0,69 |
Bewertung
Letzte 12 Monate
- KGV
- 19,0
- Kurs-Umsatz-Verhältnis
- 3,1
- Kurs-Buchwert-Verhältnis
- 2,6
- PEG
- 0,7
- Bruttomarge
- 70,4 %
- Operative Marge
- 21,0 %
- Nettomarge
- 16,6 %
- Verschuldungsgrad
- 0,5
- EV/EBITDA
- 14,2
- Eigenkapitalrendite
- 13,9 %
- Kapitalrendite (ROIC)
- 10,5 %
- Free-Cashflow-Rendite
- 5,1 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 65,0 % | 61,3 % | 69,2 % | 60,8 % | 62,8 % |
| Operative Marge | 20,3 % | 15,7 % | 16,5 % | 14,4 % | 16,2 % |
| Nettomarge | 14,4 % | 11,1 % | 11,2 % | 5,5 % | 8,7 % |
| KGV | 48,9 | 70,9 | 53,5 | 102,4 | 62,2 |
| Kurs-Umsatz-Verhältnis | 7,1 | 7,9 | 5,9 | 5,2 | 5,1 |
| Kurs-Buchwert-Verhältnis | 5,9 | 6,0 | 4,4 | 3,8 | 3,7 |
| Verschuldungsgrad | 0,5 | 0,5 | 0,5 | 0,5 | 0,6 |
| Liquidität 3. Grades | 1,6 | 1,1 | 1,3 | 1,5 | 1,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,1 % | 0,1 % |
| Unternehmenswert | 152,3 Mrd. | 142,2 Mrd. | 92,73 Mrd. | 74,21 Mrd. | 68,46 Mrd. |
| EV/EBITDA | 28,0 | 36,1 | 25,7 | 27,1 | 23,5 |
| Eigenkapitalrendite | 11,9 % | 8,5 % | 8,3 % | 4,0 % | 6,3 % |
| Kapitalrendite (ROIC) | 9,0 % | 6,1 % | 6,1 % | 3,9 % | 6,6 % |
| Free-Cashflow-Rendite | 2,6 % | 2,0 % | 2,1 % | 1,4 % | 2,2 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +19,9 % | +17,6 % | +12,3 % | +6,7 % | +19,9 % |
| Bruttogewinn | +27,2 % | +4,2 % | +27,7 % | +3,4 % | +33,8 % |
| Operatives Ergebnis | +54,5 % | +12,5 % | +28,5 % | −5,1 % | +219,8 % |
| Nettogewinn | +55,7 % | +16,4 % | +128,2 % | −32,9 % | +1.368,3 % |
| Gewinn je Aktie | +55,2 % | +16,8 % | +137,8 % | −34,8 % | +949,8 % |
| Freier Cashflow | +38,3 % | +47,6 % | +91,0 % | −28,8 % | +16,3 % |
| Dividende je Aktie | 0,0 % | −100,0 % | −49,9 % | −0,6 % | +95,7 % |
Analysten
Einstufungen · Buy
- 1Stark kaufen
- 33Kaufen
- 10Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 20,97 Mrd. | 20,82 Mrd. | 21,9 Mrd. |
| Umsatz (Tief – Hoch) | 20,9 Mrd. – 21,1 Mrd. | 20,38 Mrd. – 22,44 Mrd. | 21,64 Mrd. – 22,82 Mrd. |
| Gewinn je Aktie (Ø) | 3,16 | 3,13 | 3,37 |
| Gewinn je Aktie (Tief – Hoch) | 3,11 – 3,34 | 3,08 – 3,30 | 3,31 – 3,55 |
| Analysten | 1 | 1 | 1 |
Letzte Änderungen
- TD Cowen30. Okt. 2026Buy → Hold
- Barclays30. Okt. 2026Equal Weight
- Leerink Partners29. Okt. 2026Outperform
- RBC Capital29. Okt. 2026Outperform
- Citigroup29. Okt. 2026Neutral
- Baird29. Okt. 2026Outperform
- BTIG29. Okt. 2026Buy
- Canaccord Genuity29. Okt. 2026Buy
Quartalszahlen
Nächste Zahlen: 3. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Apr. 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,73 | 0,84 | 0,79 | 0,78 | 0,71 | 0,73 | 0,67 | 0,66 |
| Gewinn je Aktie · Tatsächlich | 0,73 | 0,86 | 0,80 | 0,80 | 0,75 | 0,75 | 0,75 | 0,70 |
| Abweichung | +0,41 % | +2,99 % | +1,52 % | +2,43 % | +5,04 % | +3,45 % | +11,44 % | +6,54 % |
| Umsatz · Tatsächlich | 5,14 Mrd. | 5,44 Mrd. | 5,2 Mrd. | 5,29 Mrd. | 5,07 Mrd. | 5,06 Mrd. | 4,66 Mrd. | 4,56 Mrd. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
Über das Unternehmen
Boston Scientific Corporation operates as a global medical technology firm, specializing in the design, production, and worldwide distribution of innovative medical devices tailored for various interventional specialties. The company's operations are strategically divided into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Through its MedSurg division, Boston Scientific provides critical diagnostic and therapeutic tools aimed at addressing conditions affecting the gastrointestinal and pulmonary systems, alongside a diverse portfolio of solutions for urological and pelvic health issues. The Rhythm and Neuro segment is dedicated to advanced cardiac rhythm management and neurological interventions. Its product offerings encompass implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) defibrillators, and pacemakers (including CRT pacemakers), all complemented by remote patient monitoring platforms. This segment also delivers sophisticated technologies for assessing and treating cardiac rate and rhythm irregularities, featuring solutions such as 3-D mapping and navigation systems, various ablation and diagnostic catheters, intracardiac ultrasound catheters, and related accessories. In the neurological domain, it furnishes spinal cord stimulator systems for managing chronic pain, indirect decompression systems, and deep brain stimulation systems. Boston Scientific's Cardiovascular segment presents an extensive array of products focused on heart and vascular health. This includes cutting-edge interventional cardiology solutions like drug-eluting coronary stent systems for treating coronary artery disease, as well as percutaneous coronary intervention (PCI) instruments designed to tackle atherosclerosis. The segment further provides intravascular catheter-directed ultrasound imaging and fractional flow reserve (FFR) devices, applicable in coronary arteries, heart chambers, and peripheral vessels, in addition to structural heart therapies. Beyond this, the company supplies stents, balloon catheters, wires, and atherectomy systems for arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents for venous conditions; and a comprehensive suite of products for cancer treatment, including peripheral embolization devices, radioactive microspheres, various ablation systems (such as cryotherapy), and micro/drainage catheters. Established in 1979, the corporation maintains its headquarters in Marlborough, Massachusetts.
Führung
- Michael F. MahoneyChairman, President & Chief Executive Officer
- Joseph FitzgeraldExecutive VP & Group President of Cardiovascular
- Arthur Crosswell ButcherExecutive Vice President and Group President of MedSurg & Asia Pacific
- Vance R. BrownEVP, General Counsel & Corporate Secretary
- Jonathan MonsonExecutive Vice President & Chief Financial Officer
- Adam SmithGeneral Manager of Global Sales & Marketing
- CEO
- Michael F. Mahoney
- Mitarbeitende
- 59.000
- Hauptsitz
- Marlborough, MA, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 29. Jan. 2018
- Website
- bostonscientific.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.